Article: Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19

Objectives: The oral antiviral drugs nirmatrelvir/ritonavir (NMV/r) and molnupiravir have been approved for early outpatient treatment of COVID-19 to prevent severe disease. Ritonavir, contained in NMV/r, is known to have significant drug-drug interactions (DDI) with several drugs frequently used by the elderly. This communication puts the problem with DDI with oral antiviral COVID-19 treatment into perspective by assessing the percentage of the elderly population at risk of severe COVID-19, using drugs with significant DDI with oral antivirals.

Methods: We estimated the size of the Danish population at risk of significant DDI with antiviral COVID-19 treatment using the number of claimed prescriptions for drugs predicted to interact with NMV/r in Denmark in 2020.

Results: Danish prescription data demonstrate the extensive use of drugs likely to interact with NMV/r. Anticoagulants contraindicated during NMV/r treatment were used by 20% of people ≥65 years and 30% of people ≥80 years. Statins that must be paused during NMV/r treatment were used by 15-18%. More than one in five used either analgesics, calcium channel blockers, or digoxin.

Conclusion: There is major potential for significant DDI with NMV/r in the elderly population at risk of severe COVID-19 disease. This calls for clear guidance for prescribers to ensure patient safety and treatment success.

Citing Articles

Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study.

Tomida T, Kimura T, Yamamoto K, Uda A, Matsumoto Y, Tamura N J Pharm Health Care Sci. 2024; 10(1):54.

PMID: 39227983 PMC: 11370042. DOI: 10.1186/s40780-024-00376-4.

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice.

Lenarda A, Ferri N, Lanzafame M, Montuori E, Pacelli L Eur Cardiol. 2024; 19:e15.

PMID: 39220617 PMC: 11363061. DOI: 10.15420/ecr.2024.04.

Associations Between COVID-19, Delirium, and 1-Year Mortality: Exploring Influences on Delirium Incidence in COVID-19 Patients.

Jang Y, Hur H, Myung W, Park E, Park H J Korean Med Sci. 2024; 39(32):e232.

PMID: 39164056 PMC: 11333801. DOI: 10.3346/jkms.2024.39.e232.

Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative Review.

Quercia R, Di Perri G, Pein C, Bodie J, Singh R, Hendrick V Infect Dis Ther. 2024; 13(5):1005-1017.

PMID: 38609668 PMC: 11098990. DOI: 10.1007/s40121-024-00959-6.

[Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients].

Rodriguez Esquiroz A, Sanz Alvarez L, Marin Marin M, Garcia Gonzalez P, Aldave Cobos P, Garjon Parra J An Sist Sanit Navar. 2023; 46(3).

PMID: 38146944 PMC: 10807205. DOI: 10.23938/ASSN.1056.

References

1.

Ko J, Danielson M, Town M, Derado G, Greenlund K, Kirley P . Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis. 2020; 72(11):e695-e703. PMC: 7543371. DOI: 10.1093/cid/ciaa1419. View

2.

Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Ac Siemieniuk R . A living WHO guideline on drugs for covid-19. BMJ. 2020; 370:m3379. DOI: 10.1136/bmj.m3379. View

3.

Marzolini C, Kuritzkes D, Marra F, Boyle A, Gibbons S, Flexner C . Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther. 2022; 112(6):1191-1200. PMC: 9348462. DOI: 10.1002/cpt.2646. View

4.

Thakur B, Dubey P, Benitez J, Torres J, Reddy S, Shokar N . A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021; 11(1):8562. PMC: 8058064. DOI: 10.1038/s41598-021-88130-w. View

5.

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W . Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022; 386(15):1397-1408. PMC: 8908851. DOI: 10.1056/NEJMoa2118542. View

6.

. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J. 2021; 43(11):1059-1103. PMC: 8690006. DOI: 10.1093/eurheartj/ehab697. View

7.

Stader F, Khoo S, Stoeckle M, Back D, Hirsch H, Battegay M . Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. J Antimicrob Chemother. 2020; 75(10):3084-3086. PMC: 7337877. DOI: 10.1093/jac/dkaa253. View

8.

Nadkarni G, Lala A, Bagiella E, Chang H, Moreno P, Pujadas E . Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020; 76(16):1815-1826. PMC: 7449655. DOI: 10.1016/j.jacc.2020.08.041. View

9.

Jayk Bernal A, Gomes da Silva M, Musungaie D, Kovalchuk E, Gonzalez A, Delos Reyes V . Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021; 386(6):509-520. PMC: 8693688. DOI: 10.1056/NEJMoa2116044. View

10.

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler K . 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10):1612-1676. PMC: 11636576. DOI: 10.1093/europace/euab065. View

Assessing the Proportion of the Danish Population at Risk of Clinically Significant Drug-drug Interactions with New Oral Antivirals for Early Treatment of COVID-19